HIV

A 2-part trial shows a new antibody that suppresses HIV when combined with antiretroviral therapy (ART).

Despite universal access to care afforded to US military service members, there is a need to improve and expand access to PrEP for those patients at highest risk for HIV infection.

On National HIV Testing Day, which takes place on June 27, Walgreens and Greater Than AIDS will team up with over 200 health and community organizations to provide free HIV testing and information at Walgreens stores in over 180 cities.

As a result of the persistent opioid epidemic, a current harm reduction initiative focuses on reducing adverse consequences in drug users.

Individuals who inject drugs are at an increased risk of developing invasive methicillin-resistant Staphylococcus aureus (MRSA).

Among HIV-positive women with diabetes, HIV control has improved over time, but diabetes control has not.

When individuals who are at risk for HIV use PrEP, and use it appropriately, risk of infection is significantly lowered.

Top news of the day from across the health care landscape.

A look at last week's top stories in the world of pharmacy.

New research investigates whether reducing the pill burden in HIV treatment regimens could improve patient adherence, retention in care, and virologic outcomes.

Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses HIV and oncology distinction programs and how these standards bring patients, physicians, and pharmacists together to align care.

A look at last week's top stories in the world of pharmacy.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Brain damage can begin early in infection, particularly during untreated infection, and can cause cognitive impairment.

Top news of the day from across the health care landscape.

The FDA has approved once-daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (Truvada) in combination with safe sex practices, to reduce the risk of sexually acquired HIV-1 in at-risk adolescents..

This article highlights several key therapeutics areas with the prescription medication.

An HIV primary care program is working to reduce the number of new HIV diagnoses and increase viral suppression rates in Long Island and Queens.

The Conference on Retroviruses and Opportunistic Infections (CROI) annually assembles researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS, and related infectious diseases.

The development and uptake of antiretroviral therapy for HIV has reduced the risk of certain cancers were previously prevalent.

Only a small portion of latently infected cells are reactivated by latency-reversing agents.

Although current guidelines recommend that HIV primary care intervals do not exceed 6 months, gaps in care up to 9 months do not worsen viral load for patients.

HIV targets and disables a pathway involved in blocking viral activity and clearing infection.

People living with HIV are at elevated risk for hyponatremia, the most common electrolyte disorder seen in hospitals.

Legalizing the sale of syringes creates accessible, affordable, and reliable sources of sterile syringes for injection drug users (IDU).

Novel technique leverages limited DNA sequences from HIV to spark a priming effect within the patient’s immune response.

Some studies have suggested that patients with HIV have not only a higher risk of lung cancer, but also an increased risk of mortality from lung cancer than patients without HIV.

Velocity of change is key when it comes to falling sodium levels. Hyponatremia is the most common electrolyte disorder seen in hospitals.

Due to lack of data on menopause and HIV, many women living with HIV infection have limited access to medical care and support.